The DEX-G2 Biomarker
Advancing Early Gastric Cancer Detection
A Breakthrough in Early Gastric Cancer Detection
At Cizzle Bio, we are pushing the boundaries of cancer diagnostics with our innovative DEX-G2 gastric cancer blood test. Designed for early-stage detection of gastric cancer, this minimally invasive, highly accurate test harnesses cutting-edge biomarker technology to provide patients and clinicians with life-saving insights—often before symptoms appear.
PROBLEMThe Urgency of Early Detection
Gastric cancer remains one of the most lethal cancers globally, mainly due to late detection and limited screening options. Traditional diagnostic methods, such as endoscopy, are invasive, expensive, and often inaccessible. DEX-G2 addresses these challenges by offering a minimally invasive, cost-effective blood test that detects gastric cancer early, when treatment is most effective.
CHALLENGES-
![]()
LATE DETECTION
Most gastric cancers are identified at advanced stages, reducing survival rates.
-
![]()
LIMITED SCREENING ACCESS
Costly and invasive procedures like endoscopy limit widespread screening.
-
![]()
UNDERSERVED POPULATIONS
High-risk regions lack adequate screening due to factors like H. pylori and genetic predispositions.
-
![]()
AWARENESS GAPS
Routine gastric cancer screening is uncommon in the U.S. due to perceived lower risk.
SOLUTIONDual-Action Biomarker Technology
DEX-G2
+
Cell-Free
miRNAs
Exosomal
miRNAs
The DEX-G2 test introduces a pioneering dual-biomarker strategy, combining:
This synergy maximizes sensitivity while maintaining exceptional specificity, ensuring accurate detection of early-stage gastric cancer.
Exosomal miRNAs: Tumor-specific biomarkers, encapsulated in exosomes—tiny vesicles released by cancer cells—providing high specificity.
Cell-Free miRNAs: Highly sensitive indicators of general health abnormalities.
Proven Clinical Performance
Specificity (Early Detection) 1
Sensitivity (Early Detection) 1
AUC (Area Under Curve): 0.96, indicating outstanding diagnostic accuracy. 1
Clinical Validation
MULTICENTER STUDY
Validated through a rigorous multicenter clinical trial conducted across high-incidence regions including Japan and South Korea.
PATIENT COHORT
More than 800 patient specimens in training and validation cohorts.
How DEX-G2 Compares to Traditional Methods
| Feature | DEX-G2 Test | Traditional Endoscopy |
|---|---|---|
| Procedure | Simple blood draw | Invasive, requires anesthesia |
| Accessibility | Broad clinical integration | Limited to specialized centers |
| Cost | Cost-effective | High cost for procedures |
| Turnaround Time | Faster results | Longer processing times |
| Patient Comfort | Minimally invasive | Can be uncomfortable/painful |
Benefits of DEX-G2
Patients
MINIMALLY INVASIVE
No anesthesia required—just a simple blood test.
EARLY DETECTION
Identifies gastric cancer before symptoms appear.
AFFORDABLE
Lower cost makes it accessible to more patients.
Clinicians
FASTER DIAGNOSIS
Quick turnaround enables timely, more informed treatment decisions.
WORKFLOW INTEGRATION
Easily integrates as a pre-endoscopy screening tool.
REDUCES UNNECESSARY PROCEDURES
Helps avoid invasive methods.
Healthcare Systems
SCALABLE
Designed for widespread screening.
COST SAVINGS
Cuts expensive diagnostic procedures.
BETTER OUTCOMES
Early detection leads to improved survival rates.
Pioneering Science. Global Partnerships.
Collaborative Innovation
Professor and Chair, Molecular Diagnostics & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
The DEX-G2 was developed from the pioneering research of renowned biomarker scientist Ajay Goel, Ph.D., AGAF, who currently serves as chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center. Dr. Goel’s groundbreaking hypothesis combined cell-free and exosomal miRNAs to create a new standard in precision diagnostics.
Key collaborators include:
Leading Asian cancer research institutions that contributed to the test’s clinical validation.
Partnerships with centers of excellence in cancer diagnostics.
Future Potential of DEX-G2 Technology
Expanding Beyond Gastric Cancer
Chronic Diseases
Other Cancers
Esophageal Cancer
Pancreatic Cancers
While DEX-G2 is currently focused on gastric cancer, its proprietary technology holds promise for:
Detecting other gastrointestinal cancers like pancreatic and esophageal cancer.
Expanding to broader liquid biopsy applications for various cancers and chronic diseases.
Saving Lives, One Test at a Time
At Cizzle Bio, our driving purpose—Detect Early. Save Lives.—inspires every breakthrough we deliver. By giving patients the power of early action and equipping physicians with precision diagnostics, we’re changing the course of cancer care and saving more lives.
FOR PATIENTS
Take proactive steps—learn how to get tested.
FOR PHYSICIANS
Learn more about how to access our DEX-G2 biomarker tests.
Join Us in Advancing Early Cancer Detection
Cizzle Bio is dedicated to providing innovative diagnostic solutions that save lives and improve quality of care. The DEX-G2 biomarker gastric cancer test is a critical step toward making early cancer detection accessible to all.
Together, we can detect earlier, treat sooner, and save more lives.
Stay updated on our advancements in technology, community impact, and industry leadership.
-
https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074
References: